NEW YORK, January 8, 2026, 13:45 EST — Regular session
Regencell Bioscience Holdings Limited shares were down 18.5% at $43.10 on Thursday, a sharp reversal after an early spike that pushed the Nasdaq-listed stock as high as $69.97. The shares opened at $62.00 and later fell to $36.01.
The whipsaw matters because it comes on top of a two-day surge that has left little room for error. RGC jumped 60.1% on Wednesday and gained 22.2% on Tuesday, and it was still up about 30% from Tuesday’s close even after Thursday’s slide. The broader Nasdaq index was down about 0.6% on the day.
Cboe’s halt log showed Regencell was paused five times for “volatility” between 9:43 a.m. and 10:29 a.m. Eastern time. Nasdaq says a “trading pause” can be triggered when a stock’s price moves about 10% from a reference print in a rolling five-minute window, a circuit breaker meant to slow disorderly trading. Cboe Global Markets+1
Trading stayed heavy. More than 3 million shares had changed hands by early afternoon, versus a 20-day average volume of about 709,000, Stock Analysis data show; it also lists Regencell’s free float — shares available for public trading — at roughly 18.4 million, with insiders holding about 88.6%.
There was no immediate company statement explaining the swings. Regencell carried out a 38-for-1 forward stock split in June 2025, paid in the form of a stock bonus, and kept the RGC ticker, it disclosed in a Form 6-K.
But the downside case is plain. In its latest annual report, the company warned: “There is substantial doubt regarding our ability to continue as a going concern” — an accounting term that signals it may not have enough funding to keep operating as planned. The filing also reported net losses of $3.58 million for the year ended June 30, 2025 and $4.36 million a year earlier. SEC
